Nf2-associated meningioma model
OwnerLong-Sheng CHANGinventor
Life of this patent
Estimating the term…
Abstract
A method of generating a tumor cell line is described. The method includes transfecting meningioma cells obtained from a benign tumor with telomeres reverse transcriptase to provide telomerase-immortalized meningioma cells, and passaging the telomerase-immortalized meningioma cells in growth medium together with untransformed meningioma cells until the untransformed cells undergo senescence to provide a tumor cell line comprising telomerase-immortalized meningioma cells. A tumor cell line including telomerase-immortalized meningioma cells obtained from a benign tumor is also described, as well as an animal model of NF2-deficient meningioma that includes a mammal implanted with telomerase-immortalized, luciferase-expressing meningioma cells obtained from a benign tumor.
Claims19
A method of generating a tumor cell line, comprising immortalizing meningioma cells obtained from a benign tumor by introducing telomerase reverse transcriptase to provide telomerase immortalized meningioma cells, and passaging the telomerase immortalized meningioma cells in growth medium together with untransformed meningioma cells until the untransformed cells undergo senescence to provide a tumor cell line comprising telomerase-immortalized meningioma cells.
A tumor cell line comprising telomerase-immortalized meningioma cells obtained from a benign tumor.
An animal model of NF2-deficient meningioma, comprising a mammal implanted with telomerase-immortalized, luciferase-expressing meningioma cells obtained from a benign tumor.
A method of treating meningioma in a subject in need thereof by administering a therapeutically effective amount of brigatinib to the subject.
Dependencies are inferred from the claim text.